Pre-transplant depression may impair post-HCT outcomes
Areej El-Jawahri, M.D., from the Massachusetts General Hospital in Boston, and colleagues analyzed data from the Center for International Blood and Marrow Transplant Research (CIMBTR) to compare outcomes for adult patients with hematologic malignancies with and without depression after autologous (3,786 patients) or allogeneic (7,433 patients) HCT.
The researchers found that among patients who underwent allogeneic HCT between 2008 and 2012, 15 and 85 percent, respectively, had pre-transplant depression and no depression. Pre-transplant depression correlated with lower overall survival (hazard ratio, 1.13; 95 percent confidence interval [CI], 1.04 to 1.23; P = 0.004) and with increased incidence of grade 2 to 4 acute graft-versus-host disease (hazard ratio, 1.25; 95 percent CI, 1.14 to 1.37; P < 0.0001). There was a correlation for pre-transplant depression with fewer days alive and out of the hospital (means ratio, 0.97; 95 percent CI, 0.95 to 0.99; P = 0.004). Among patients who underwent autologous HCT, 13.5 and 86.5 percent, respectively, had pre-transplant depression and were without depression. In autologous HCT, pre-transplant depression was not associated with overall survival (hazard ratio, 1.15; 95 percent CI, 0.98 to 1.34; P = 0.096), but there was a correlation with fewer days alive and out of the hospital (means ratio, 0.98; 95 percent CI, 0.97 to 0.99; P = 0.002).
"Patients with pre-transplant depression represent a population that is at risk for post-transplant complications," the authors write.
The CIBMTR was partially funded by several pharmaceutical companies.
Copyright © 2017 HealthDay. All rights reserved.